TZ9

TZ9 is a selective Rad6 inhibitor. TZ9 inhibits Rad6B-induced histone H2A ubiquitination, downregulates intracellular β-catenin, induces G2-M arrest and apoptosis, and inhibits the proliferation and migration of metastatic human breast cancer cells[1].

Product Specifications

CAS Number

[1002789-86-7]

UNSPSC

12352005

Target

Apoptosis; E1/E2/E3 Enzyme

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/TZ9.html

Concentration

10mM

Purity

99.45

Solubility

DMSO : ≥ 40 mg/mL

Smiles

O=C(OCC1=NC(N)=NC(NC2=CC=CC=C2)=N1)C3=CC=C([N+]([O-])=O)C=C3

Molecular Formula

C17H14N6O4

Molecular Weight

366.33

References & Citations

[1]Sanders MA, et al. Novel inhibitors of Rad6 ubiquitin conjugating enzyme: design, synthesis, identification, and functional characterization. Mol Cancer Ther. 2013 Apr;12 (4) :373-83.